Gilead Sciences, Inc.

Nmd Pharma A/s

Inthera Bioscience Ag

Epitherapeutics Aps

Marc A Labelle

Farman Ullah

Ramkrishna Reddy Vakiti

Thomas Boesen

Mukund Mehrotra

Thomas Holm Pedersen

Neerja Saraswat

Cyril Cook

Qasim Khan

Claus Elsborg Olesen

Lars J S Knutsen

Ying Yang

Jean-d'amour K Twibanire

Ulrich Kessler

Kevin R D Johnson

Valentino Cattori

Matinder Kaur

Martin Broch-Lips

Ole Bækgaard Nielsen

Dastagiri Dudekula

Utpal Sharma

Nicholas Kelly

Martin E Cooper

Rui Zhang

Martin Broch-Lipps

Paul Brian Little

Rafiq A Taj

Rajesh Kumar

Ole Baekgaard Nielsen

The present invention relates to novel compounds of formula (I) or formula (Ia) pharmaceutically-acceptable salts, hydrates, solvates, or stereoisomers thereof, and pharmaceutical compositions of these compounds which are useful for preventive and therapeutic use in human and veterinary medicine.

Oxopiperazine derivatives

The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.

Compounds for the treatment of neuromuscular disorders

The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel. The compounds include phenoxy propanoic acid, phenoxy propanoate, and phenoxy butanoate compounds.

The present invention relates to compositions comprising compounds for use in treating, ameliorating and/or preventing neuromuscular disorders. The compounds as defined herein preferably inhibit the ClC-1 ion channel. The invention further relates to methods of treating, preventing and/or ameliorating neuromuscular disorders, by administering said composition to a person in need thereof.

Compounds for use in treating neuromuscular disorders

The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament. The compounds take the form 

Inhibitors of histone demethylases

The present application relates to compounds being of Formula (I), (II), (III), (IV), (V), (VI), (IIIa), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), and (IIIg). Compounds of Formula (I) have the structure: wherein Q, R, R, R, M, A and Y are as defined herein. The compounds of the application can modulate the activity of histone demethylases (HDMEs), and can be useful for the prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, e.g., cancer.

Compounds and methods for inhibiting histone demethylases

Compounds of the form In which Q is selected from &#x2014;CH&#x2550;NR, &#x2014;W, &#x2014;CHNHR, &#x2014;CH&#x2550;O and &#x2014;CH(OR)capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.

Growing community of inventors

Bedford, NH, United States of America

Marc A Labelle